Alpha Financial Partners LLC Has $248,000 Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

Alpha Financial Partners LLC lifted its position in shares of Novo Nordisk A/S (NYSE:NVO) by 8.1% in the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,739 shares of the company’s stock after buying an additional 130 shares during the quarter. Alpha Financial Partners LLC’s holdings in Novo Nordisk A/S were worth $248,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of NVO. First PREMIER Bank acquired a new stake in Novo Nordisk A/S in the 1st quarter worth about $25,000. 1620 Investment Advisors Inc. acquired a new stake in Novo Nordisk A/S during the second quarter worth approximately $25,000. Dixon Mitchell Investment Counsel Inc. bought a new position in Novo Nordisk A/S during the 1st quarter worth $26,000. Orion Capital Management LLC acquired a new position in Novo Nordisk A/S in the 1st quarter valued at $26,000. Finally, Gilliland Jeter Wealth Management LLC lifted its position in shares of Novo Nordisk A/S by 200.0% during the 2nd quarter. Gilliland Jeter Wealth Management LLC now owns 180 shares of the company’s stock valued at $26,000 after acquiring an additional 120 shares during the period. Institutional investors own 11.54% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on NVO shares. Argus boosted their price target on Novo Nordisk A/S from $125.00 to $160.00 and gave the company a “buy” rating in a research note on Monday, June 10th. StockNews.com cut Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Monday, August 19th. The Goldman Sachs Group assumed coverage on Novo Nordisk A/S in a research note on Thursday, May 30th. They issued a “buy” rating and a $156.00 price target on the stock. BMO Capital Markets dropped their price objective on Novo Nordisk A/S from $170.00 to $160.00 and set an “outperform” rating for the company in a research report on Thursday, August 8th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a research report on Monday. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat, Novo Nordisk A/S has a consensus rating of “Moderate Buy” and an average target price of $145.17.

Novo Nordisk A/S Trading Down 0.1 %

NYSE NVO opened at $136.90 on Tuesday. The company has a market cap of $614.34 billion, a price-to-earnings ratio of 47.21, a price-to-earnings-growth ratio of 1.48 and a beta of 0.42. Novo Nordisk A/S has a twelve month low of $86.96 and a twelve month high of $148.15. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.46. The business’s fifty day moving average is $133.90 and its 200 day moving average is $133.14.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Wednesday, August 7th. The company reported $0.65 EPS for the quarter, missing analysts’ consensus estimates of $0.71 by ($0.06). Novo Nordisk A/S had a net margin of 34.86% and a return on equity of 87.43%. The firm had revenue of $9.82 billion for the quarter, compared to analyst estimates of $9.91 billion. As a group, sell-side analysts expect that Novo Nordisk A/S will post 3.11 EPS for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The firm also recently declared a semi-annual dividend, which was paid on Monday, August 26th. Shareholders of record on Friday, August 16th were given a $0.5126 dividend. This represents a yield of 0.7%. The ex-dividend date of this dividend was Friday, August 16th. Novo Nordisk A/S’s dividend payout ratio (DPR) is currently 24.83%.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.